sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_8545> bl:category bl:Disease .
  sub:association rdf:object <http://purl.obolibrary.org/obo/DOID_8545> ;
    rdf:predicate bl:treats ;
    rdf:subject <https://identifiers.org/drugbank:DB01219> ;
    a rdf:Statement ;
    rdfs:label "dantrolene sodium capsules are indicated in controlling the manifestations of clinical spasticity resulting from upper motor neuron disorders e g spinal cord injury stroke cerebral palsy or multiple sclerosis it is of particular benefit to the patient whose functional rehabilitation has been retarded by the sequelae of spasticity such patients must have presumably reversible spasticity where relief of spasticity will aid in restoring residual function dantrolene sodium capsules is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders if improvement occurs it will ordinarily occur within the dosage titration see dosage and administration occasionally subtle but meaningful improvement in spasticity may occur with dantrolene sodium capsules therapy in such instances information regarding improvement should be solicited from the patient and those who are in constant daily contact and attendance with him brief withdrawal of dantrolene sodium capsules for a period of 2 to 4 days will frequently demonstrate exacerbation of the manifestations of spasticity and may serve to confirm a clinical impression a decision to continue the administration of dantrolene sodium capsules on a long term basis is justified if introduction of the drug into the patient s regimen produces a significant reduction in painful and or disabling spasticity such as clonus or permits a significant reduction in the intensity and or degree of nursing care required or rids the patient of any annoying manifestation of spasticity considered important by the patient himself oral dantrolene sodium capsules is also indicated preoperatively to prevent or attenuate the development of signs of malignant hyperthermia in known or strongly suspect malignant hyperthermia susceptible patients who require anesthesia and or surgery currently accepted clinical practices in the management of such patients must still be adhered to careful monitoring for early signs of malignant hyperthermia minimizing exposure to triggering mechanisms and prompt use of intravenous dantrolene sodium and indicated supportive measures should signs of malignant hyperthermia appear see also the package insert for intravenous dantrolene sodium oral dantrolene sodium capsules should be administered following a malignant hyperthermic crisis to prevent recurrence of the signs of malignant hyperthermia" ;
    bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    bl:provided_by <https://w3id.org/um/NeuroDKG> ;
    bl:relation schema:PreventionIndication .
  <https://identifiers.org/drugbank:DB01219> bl:category bl:Drug .
}